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Purpose: To investigate whether common genetic variants in the complement component 1 inhibitor gene (serpin
peptidase inhibitor, clade G, member 1, SERPING1) are associated with polypoidal choroidal vasculopathy (PCV) in a
Chinese Han population.
Methods: DNA samples were obtained from 118 PCV patients and 115 healthy subjects. Data derived from the HapMap
project were used to select tag single nucleotide polymorphisms (SNPs) across the extended SERPING1 region. A
previously reported age-related macular degeneration-related risk factor (rs2511989) was forcibly included. Genotyping
of each tag SNP was performed by PCR restriction fragment length polymorphism and direct DNA sequencing techniques.
Results: Four SNPs for SERPING1, rs2509897, rs1005510, rs11603020, and rs2511989, were chosen as tag SNPs. None
of these tag SNPs were associated with PCV, according to the single-SNP association test (p=0.41–0.83). Evaluation of
common haplotypes across SERPING1 did not reveal any association with PCV (p=0.49–0.82).
Conclusions: We found no evidence to support the role of any common SERPING1 variants, including the rs2511989
variant, in the susceptibility to PCV in a Chinese Han population.
Polypoidal  choroidal  vasculopathy  (PCV)  is  a
hemorrhagic  and  exudative  macular  disease  that  shows
distinct forms of choroidal vascular abnormalities, including
abnormal choroidal vascular networks and polypoidal lesions
at their borders [1-3]. PCV has a particularly high incidence
among  the  exudative  age-related  macular  degeneration
(AMD)  in  Asian  populations,  accounting  for  24.5%  of
exudative AMD in the Chinese population [4] and 54.7% in
the Japanese population [5] compared with only 8%–13% in
Caucasians [3].
PCV shares many similarities with neovascular AMD,
including  demography  [4,5],  pathology  [6-8],  and
manifestation [4,5]. Due to the similarities between PCV and
neovascular AMD, most genetic risk factors for PCV were
found based on previous genetic studies for AMD patients.
Several genetic risk factors for AMD have been established,
including  the  complement  factor  H  (CFH)  gene  on
chromosome  1q32  [9-13]  and  two  tightly  linked  genes,
namely age-related maculopathy susceptibility 2 (ARMS2)
and  high-temperature  requirement  factor  A1  (HTRA1)  on
chromosome  10q26  [14-16].  Several  recent  studies  have
shown a strong association between PCV and these variants
[17-22].
Since the discovery of the association between AMD and
variants in CFH, several other genes regulating or involved in
the alternative pathway of complement activation have been
found to show a strong association with AMD, including those
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coding for complement component 3 (C3) [23], complement
factor B (CFB), and complement factor 2 (C2) [24]. The
complement factor 1 (C1) inhibitor is encoded by the serpin
peptidase inhibitor, clade G, member 1 (SERPING1) gene
(GenBank NM_000062) and is a member of a large family of
serine proteases. The protein encoded by SERPING1 is a key
regulator of the classical pathway for complement activation.
It has been reported to downregulate the alternative pathway
in vitro by binding to C3b and inhibiting the binding of CFB
to C3b [25]. Recently, Ennis et al. reported a protective effect
on AMD for the minor allele of rs2511989 within intron 6 of
SERPING1 [26]. However, the association was not replicated
in another study conducted by Park et al. [27].
Considering  the  similarities  between  PCV  and
neovascular AMD and the strong association between PCV
and  CFH,  we  hypothesized  that  polymorphisms  in  the
SERPING1  gene,  another  regulator  of  the  complement
system, might play a role in the development of PCV. In this
study,  we  genotyped  four  tag  single  nucleotide
polymorphisms (SNPs) that are highly representative of the
common  genetic  variations  in  the  SERPING1  region  and
analyzed the associations between these variants and PCV in
a Chinese Han population.
METHODS
Study participants: The study protocol was approved by the
institutional  review  board  at  the  Zhongshan  Ophthalmic
Center of Sun Yat-sen University, Guangzhou, China, and
performed in accordance with the Declaration of Helsinki.
Informed  consent  was  obtained  from  all  subjects  before
participation in this study. All cases and controls included in
this study were Chinese Han individuals recruited from the
Zhongshan Ophthalmic Center.
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231All PCV patients underwent ophthalmic examinations,
including  visual  acuity  measurements,  slit-lamp
biomicroscopy, ophthalmoscope, color fundus photographs,
fluorescein angiography, and indocyanine green angiography
(ICGA). The diagnosis of PCV was based on identification of
polypoidal  choroidal  vascular  dilations  with  or  without
branching inner choroidal vessels on ICGA. Thus, all PCV
patients enrolled in this study met the criteria of definitive
cases of PCV, as proposed by the Japanese Study Group of
Polypoidal Choroidal Vasculopathy [28]. Definitive cases of
PCV must satisfy at least one of the following two criteria: (1)
protruding orange-red lesions visible on fundus examination;
(2) characteristic polypoidal lesions evident (Figure 1) on
ICGA. Patients with other neovascularized maculopathies,
such  as  neovascular  AMD,  pathologic  myopia,  angioid
streaks,  presumed  ocular  histoplasmosis,  and  retinal
angiomatous proliferation, were excluded. The characteristics
of the study group are summarized in Table 1.
All  control  subjects  underwent  comprehensive
ophthalmic  examinations,  and  those  with  macular
degeneration of any cause, macular changes (such as drusen
or pigment abnormalities), or media opacities preventing clear
visualization  of  the  macula  were  excluded  from  the
recruitment.  All  control  subjects  were  unrelated  to  case
subjects and were aged ≥50 years.
Single  nucleotide  polymorphism  selection:  SNPs  across
SERPING1, including 5 kb upstream and downstream in the
international  haplotype  map  (HapMap)  [29]  for  the  Han
Chinese in Beijing, China (CHB), were used to select tag
SNPs. SNPs with a minor allele frequency above 5% were
evaluated for linkage disequilibrium (LD) using Haploview
software 4.1 [30]. A minimum threshold value of 0.8 for the
r2 parameter was set in the Haploview software. r2 represents
the multivariate coefficient of determination for all alleles that
are to be captured. A previously reported SNP (rs2511989)
was included as a tag SNP, using the forced inclusion option.
The selected SNPs and SNPs captured by these SNPs are
given in Table 2.
Genotyping of participants: Peripheral blood sample were
anticoagulated  with  ethylene  diamine  tetraacetic  acid  and
stored at −80 °C before use. Genomic DNA from the blood
by Nucleospin ®Blood XL kit (Macherey-Nagel GmbH &
Co., KG Düren, Germany). The kit contains a silica membrane
which can specifically bind DNA. After binding, DNA can be
washed out by elute buffer. Genotyping was performed using
PCR restriction fragment length polymorphism and direct
sequencing.
Figure 1. Clinical photos of polypoidal choroidal vasculopathy (PCV). A: Color fundus photograph of a patient with PCV. Several orange
lesions are visible in the macula. Hemorrhage is visible between the orange lesions and the optic disk. B: The diagnosis of PCV was confirmed
with indocyanine green angiography (ICGA). Abnormal choroidal vascular networks and characteristic polypoidal lesions are visible in the
macula, corresponding to the orange lesion in the color fundus photograph.
TABLE 1. CHARACTERISTICS OF THE STUDY POPULATION
 Demographic characteristics PCV Controls p value
Number of subjects 118 115  
Gender (male/female) 78/40 69/46 0.335
Mean age±SD (years) 65±8.4 69±8.7 <0.001
Age range (years) 43–85 50–87  
Abbreviations: PCV represents Polypoidal Choroidal Vasculopathy; SD represents standard deviation.
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232The target DNA in SERPING1 was amplified by PCR
using  relevant  primers.  The  primers  for  each  SNP  were
designed using Primer Premier 5.0 software (Premier Biosoft
International,  Palo  Alto,  CA).  The  primer  sequences  and
restriction enzymes (New England Biolabs, Ipswich, MA)
used for each SNP are presented in Table 3.
Each PCR was performed in 20 μl of solution containing
10 μl of 2× Power Taq PCR MasterMix (Bioteke Corporation,
Beijing, China), 8 pmol of primers, and 50 ng of genomic
DNA. The cycling profile was: initial denaturation at 95 °C
for 3 min, 33 cycles consisting of 95 °C for 30 s, proper
annealing temperature (Table 3) for 30 s, 72 °C for 30 s, and
a final extension for 10 min at 72 °C.
The digestion conditions contained 7.25 μl pure water,
1 μl NEB buffer, 0.25 μl enzyme and 1.5 μl PCR product for
enzyme  BslI,  BbvI,  and  DdeI.  The  reaction  conditions
contained 7.15 μl pure water, 1 μl NEB buffer, 0.1 μl BSA,
0.25 μl enzyme and 1.5 μl PCR product for enzyme BstNI.
The reaction temperature for enzyme BslI was 55 °C, for
enzyme BstNI was 60 °C, and for enzyme BbvI and DdeI was
37  °C.  After  digestion,  all  fragments  were  resolved  by
electrophoresis on 8% polyacrylamide gel (PAG) at 30 W for
2 h. Subsequently, the PAG was silver stained [31]. Briefly,
the gels were fixed with 1% nitric acid for 5 min and 10%
alcohol for 3min. After several changes of water, the gels were
incubated in 0.1% silver nitrate for 25 min. Then the gels were
developed  in  3%  sodium  carbonate  and  the  reaction  was
terminated with acetic acid. To confirm the accuracy of the
method used, randomly selected subjects (10% of all samples)
were  analyzed  by  direct  sequencing  (Shanghai  Sangon
Biologic  Engineering  Technology  &  Service  Co.  Ltd.
Shanghai, China). All the primers used for direct sequencing
are available on request.
Statistical analysis: Age and gender differences between PCV
and control subjects were assessed using the unpaired Student
t-test and χ2 test, respectively, with SPSS 13.0 for windows
software  (SPSS  Inc.,  Chicago,  IL).  Deviations  from  the
Hardy–Weinberg equilibrium were tested using the exact test
implemented in the software package PLINK, v1.06 [32].
Genotypes and allele frequencies between cases and controls
were evaluated for each SNP using the chi-square test with
PLINK.  The  odds  ratio  (OR)  and  corresponding  95%
confidence interval (CI) were calculated relative to the minor
allele. Haploview software was used to assess LD patterns and
haplotype  association  statistics.  Haplotype  blocks  were
determined using the “4-gamete rule” option implemented in
Haploview. A p value of <0.05 was considered statistically
significant.
RESULTS
A total of 233 subjects were enrolled in this study, comprising
118 unrelated patients with PCV and 115 healthy control
individuals (Table 1). The mean ages were 65±8.4 years for
TABLE 2. SELECTED SNP AND SNPS CAPTURED BY THESE SNPS
Selected SNP SNPs captured by current SNP
rs2509897 rs2511990, rs2509897, rs2729376
rs1005510 rs1005510, rs1005511, rs2511988
rs11603020 rs4926, rs11229066, rs11229067, rs3824988, rs11603020, rs3758919
rs2511989 rs2508443, rs2511989
Abbreviations: SNP represents single nucleotide polymorphism.
TABLE 3. PRIMERS AND RESTRICTION ENZYME USED IN THIS STUDY
SNP Primer sequence AT (°C) Enzyme PCR product Enzyme products
rs2509897 F:TGGGAGCAGGTCTAGGATT 60.5 BslI (NEB) 170 bp 29 bp and 141 bp
R: CAGGAAGAGCTTTAGTGAG
rs1005510 F: GGCACAGTCCTCTAAAATAC 57.7 BbvI (NEB) 204 bp 102 bp and 102 bp
R: CCTGACTATCCCTCATCTT
rs11603020 F:TGGCAAAATGTGAGTCGTGTTCCT 63 BstNI (NEB) 293 bp 223 bp and 70 bp
R: GCCAGTTGGGATCCTCTGGGC
rs2511989 F: GAAGAAGGACTTTCAACTG 54.8 DdeI (NEB) 102 bp 21 bp and 81 bp
R:TGAGAGGCAAATTCACTC
Abbreviations: NEB represents New England Biolabs, Ipswich, MA; SNP represents single nucleotide polymorphism; AT
represents annealing temperature.
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233PCV patients and 69±8.7 years for healthy controls (p<0.001).
The percentage of males was 66.1% in the PCV group and
60% in the control group (p=0.335).
Four SNPs were chosen as tag SNPs. Genotypes were
determined successfully by restriction enzyme digestion in all
subjects for the four SNPs and confirmed by direct sequencing
(Figure 2). None of the four SNPs genotyped in this study
showed  significant  deviation  from  Hardy–Weinberg
equilibrium  tests  in  both  case  and  control  subjects  (all
p>0.252).
Figure  2.  PCR  restriction  fragment
length polymorphism (PCR-RFLP) and
DNA  sequencing  for  all  tag  single
nucleotide polymorphisms (SNPs). A:
Restriction  analysis  for  rs2509897
resulted  in  digestible  fragment  (C/C),
undigestible  fragment  (T/T),  and
heterozygote  (C/T).  B:  Direct
sequencing  confirmed  the  restriction
patterns for rs2509897. C: Restriction
analysis  for  rs1005510  resulted  in
digestible fragment (A/A), undigestible
fragment (G/G), and heterozygote (A/
G). D. Reverse sequencing confirmed
the restriction patterns for rs1005510.
E: Restriction analysis for rs11603020
resulted  in  digestible  fragment  (C/C),
undigestible  fragment  (T/T),  and
heterozygote  (C/T).  F:  Reverse
sequencing  confirmed  the  restriction
patterns for rs11603020. G. Restriction
analysis  for  rs2511989  resulted  in
digestible fragment (A/A), undigestible
fragment (G/G), and heterozygote (A/
G). H: Reverse sequencing confirmed
the restriction patterns for rs2511989.
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234The minor allele frequencies in each group for all tag
SNPs genotyped and the results of the single-SNP association
study are summarized in Table 4. The results of genotype
frequencies for all tag SNPs are shown in Table 5. None of
the four tag SNPs showed a significant association with PCV
(Table 4 and Table 5). The OR for PCV in rs2511989 A/G
heterozygotes compared with wild-type G/G homozygotes
was 1.08 (95% CI 0.60–1.95). A similar comparison of the A/
A homozygotes with the wild type yielded an OR of 3.04
(0.31–29.77).
The pairwise LD structure was constructed with all SNPs
genotyped (Figure 3). Three SNPs, rs2509897, rs1005510,
and rs11603020, were placed within one haplotype block, and
we examined haplotypes based on these three SNPs in the
haplotype  block.  Details  of  the  haplotypes  and  their
frequencies in PCV and control subjects are presented in Table
6. No particular haplotype was found to be associated with a
risk of PCV.
DISCUSSION
In this study we investigated the association of SERPING1
polymorphisms with PCV in a Chinese Han population. Our
study showed that none of the four tag SNPs for SERPING1
were associated with PCV. The genotyping methods used in
this study were different from those in a previous study [26].
As  shown  previously  [33,34],  different  genotyping
technologies could yield inconsistent genotyping results. To
validate  the  results  of  genotyping,  two  methods,  PCR
restriction  fragment  length  polymorphism  and  direct
sequencing, were used in this study.
PCV shares many similarities with neovascular AMD.
However,  the  histopathological  findings  remain  confusing
[35], and there are distinct clinical differences between PCV
and neovascular AMD, including morphologic features and
disease progression [3], as well as response to therapy [36,
37]. The clinical differences may indicate different genetic
characteristics between PCV and neovascular AMD.
The  complement  system  is  a  powerful  component  of
innate immunity, which recognizes pathogens and unwanted
host material and facilitates their elimination [38]. Activation
of complement leading to membrane attack complex (MAC)
formation can be triggered via three known pathways (the
classical,  lectin,  and  alternative  pathways).  The  classical
pathway is generally initiated by antibody interactions with
foreign antigens. The protein encoded by SERPING1 is an
important complement regulator and plays a crucial part in
suppressing  the  activity  of  C1.  Inhibition  of  C1  prevents
activation of C2 and C4, thus the cleavage of C3 into the
TABLE 4. ASSOCIATION TEST FOR MINOR ALLELE FREQUENCY BETWEEN PCV AND CONTROL SUBJECTS
SNP Position (bp) Minor allele PCV, n Control, n OR 95% CI p value
rs2509897 57119193 T 38 (0.161) 33 (0.144) 1.15 0.69–1.90 0.5984
rs1005510 57123798 G 61 (0.259) 52 (0.226) 1.19 0.78–1.83 0.4147
rs11603020 57130908 C 24 (0.102) 22 (0.096) 1.07 0.58–1.97 0.8269
rs2511989 57134901 A 37 (0.157) 31 (0.135) 1.19 0.71–2.00 0.5013
Abbreviations: CI represents confidence interval; OR represents odds ratio; PCV represents polypoidal choroidal vasculopathy;
SNP represents single nucleotide polymorphism.
TABLE 5. ASSOCIATION TEST FOR GENOTYPE BETWEEN PCV AND CONTROL SUBJECTS
SNP Genotype PCV, n (%) Control, n (%) OR 95%CI P value
rs2509897 CC 83 (70.3) 84 (73.0)     0.8543
CT 32 (27.1) 29 (25.2) 1.12 0.70–2.01
TT 3 (2.5) 2 (1.7) 1.52 0.25–9.32
rs1005510 AA 63 (53.4) 69 (60.0)     0.5643
AG 49 (41.5) 40 (34.8) 1.34 0.78–2.30
GG 6 (5.1) 6 (5.2) 1.1 0.34–3.57
rs11603020 TT 96 (81.4) 95 (82.6)     0.9647
CT 20 (16.9) 18 (15.7) 1.1 0.55–2.21
CC 2 (1.7) 2 (1.7) 0.99 0.14–7.17
rs2511989 GG 84 (71.2) 85 (73.9)     0.5963
AG 31 (26.3) 29 (25.2) 1.08 0.60–1.95
AA 3 (2.5) 1 (0.9) 3.04 0.31–29.77
Abbreviations: SNP represents single nucleotide polymorphism; PCV represents polypoidal choroidal vasculopathy; OR
represents  odds ratio; 95%CI represents 95% confidence intervals. OR and 95%CI were calculated to estimate risk size as
comparison of the homozygote and heterozygote versus wild-type homozygote.
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235anaphylatoxin C3a and the major fragment C3b is inhibited.
C3b  subsequently  binds  foreign  structures  and  forms  a
complex with CFB that cleaves C5 (C3bBb, C5 convertase).
This complex amplifies the complement response, resulting
in the formation of MAC. Variants within several genes that
code for proteins involved in the complement system are
recognized to either significantly increase the risk of AMD
(CFH [9-11] and C3 [23]) or decrease the risk (SERPING1
[26], C2 and CFB [24]).
Due to the similarities between PCV and AMD, several
studies were conducted to test the association between PCV
and  complement  components.  Previous  studies  [39,40]
showed  that  several  CFH  variants
(rs3753394,rs551397,rs800292,rs2274700,  and  rs1329428)
but not the Y402H variant that is the most common variant in
western AMD patients, were significantly associated with
neovascular  AMD  in  Chinese  cohorts.  A  significant
association between PCV and CFH variants (rs3753394 and
rs800292) was observed in another Chinese cohort [18]. Thus
it appeared that the alternative pathway might be implicated
in the pathogenesis of both PCV and AMD.
Figure  3.  Linkage  disequilibrium
structure of serpin peptidase inhibitor,
clade  G,  member  1  (SERPING1).
Linkage  disequilibrium  (LD)  was
measured using data from all subjects in
this study. The haplotype blocks were
determined using the “4-gamete rule”
option implemented in the Haploview
software. Each box provides estimated
statistics  of  the  coefficient  of
determination (r2), with darker shades
representing stronger LD.
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236Several studies showed a protective effect on neovascular
AMD for C2 and BF [24,41]. However, the association was
not observed between PCV and C2 in a Chinese cohort [18].
Ennis  [26]  reported  a  protective  effect  on  AMD  for
SERPING1;  however,  no  association  between  PCV  and
SERPING1  was  observed  in  this  study.  Both  C2  and
SERPING1 are crucial regulators of the classic complement
pathway. Given the published data and the results of this
study, we hypothesized that the classic pathway might play a
minor  role  in  the  pathogenesis  of  PCV  compared  with
neovascular AMD. However, further studies containing larger
numbers of PCV and neovascular AMD patients should be
conducted to test our hypotheses.
Drusen  is  abnormal  accumulations  of  extracellular
material that forms between the basal surface of the retinal
pigmented  epithelium  and  Bruch’s  membrane.  It  is  a
significant  risk  factor  for  the  development  of  AMD  [42].
Previous  studies  showed  that  several  complement
components were found in drusen, including C3a and C5b-9
[43,44]. The prevalence of large soft drusen in the fellow eyes
of unilateral PCV patients was much less than that among
AMD patients [5,45]. This clinical difference between PCV
and AMD can be partly explained by the genetic differences
between them.
Potential limitations of our study should be mentioned.
First, the PCV and control groups were not completely age
matched.  Second,  we  did  not  sample  enough  neovascular
AMD patients and no comparison was conducted between
PCV and neovascular AMD in this Chinese Han cohort. Third,
no mechanistic and functional evaluations were conducted in
this study.
In summary, this study has been conducted to investigate
the association of SERPING1 polymorphisms with PCV. To
our knowledge, this issue has not been investigated to date.
We found no evidence to support the role of any common
SERPING1  variation,  including  rs2511989,  in  the
susceptibility to PCV in a Chinese Han population; thus the
focus  may  be  shifted  to  other  loci  in  future  PCV-related
genetic association studies.
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